Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05495464
Title	A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	M.D. Anderson Cancer Center
Indications	mantle cell lymphoma
Therapies	Cyclophosphamide + Fludarabine Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Acalabrutinib + Rituximab
Age Groups:	adult \| senior
Covered Countries	USA